Antivirals by Class Exam 2024 PDF
Document Details
Uploaded by LightHeartedCerberus
Union University College of Pharmacy
Tags
Summary
This document appears to be a list of antiviral agents organized by class. It could be study notes or lecture material.
Full Transcript
+-----------------+-----------------+-----------------+-----------------+ | **[ANTI-INFLUEN | **[HUMAN | **[ANTI-HIV | **[ANTI-HIV | | ZA | PAPILLOMA VIRUS | AGENTS]{.underl | AGENTS]{.underl | | AGENTS]{.underl | AGENTS]{.underl | ine}** | ine}** | | in...
+-----------------+-----------------+-----------------+-----------------+ | **[ANTI-INFLUEN | **[HUMAN | **[ANTI-HIV | **[ANTI-HIV | | ZA | PAPILLOMA VIRUS | AGENTS]{.underl | AGENTS]{.underl | | AGENTS]{.underl | AGENTS]{.underl | ine}** | ine}** | | ine}** | ine}** | | | | | | **Nucleoside/Nu | **Pharmacokinet | | **Viral | **Immune | cleotide | ic | | Uncoating | modulating** | Analogues | Enhancers** | | Inhibitors** | | Reverse | | | | **[ANTI-HEPATIT | Transcriptase | **Fusion | | **Viral Release | IS | Inhibitors | Inhibitors** | | Inhibitors** | AGENTS]{.underl | (NRTIS)** | | | | ine}** | | **HIV-1 Capsid | | **Viral | | Abacavir | Inhibitors** | | replication | **Nucleoside/Nu | (Ziagen^®^) | | | Inhibitors** | cleotide | | **Single Tablet | | | Analogues | Emtricitabine | Regimens** | | **[HERPES | (Reverse | (Emtriva^®^) | | | SIMPLEX VIRUS | Transcriptase | | **COVID-19 | | AND VARICELLA | Inhibitors) -- | Lamivudine | Agents** | | ZOSTER VIRUS | (HBV)** | (Epivir^®^) | | | AGENTS]{.underl | | | | | ine}** | Lamivudine | Tenofovir | | | | (Epivir-HBV^®^) | disoproxil | | | **Fusion | | fumarate | | | inhibitors** | Adefovir | (Viread^®^) | | | | dipivoxil | | | | **Nucleoside | (Hepsera^®^) | Tenofovir | | | and Nucleotide | | alafenamide | | | Analogues** | Tenofovir | (Vemlidy^®^) | | | | disoproxil | | | | Acyclovir | fumarate | Tenofovir DF + | | | (Zovirax^®^) | (Viread^®^) | Emtricitabine | | | | | (Truvada^®^) | | | Valacyclovir | Tenofovir | | | | (Valtrex^®^) | alafenamide | Tenofovir AF + | | | | (Vemlidy^®^) | Emtricitabine | | | Famciclovir | | (Descovy^®^) | | | (Famvir^®^) | Entecavir | | | | | (Baraclude^®^) | Abacavir + | | | Penciclovir | | Lamivudine | | | (Denavir^®^) - | Telbivudine | (Epzicom^®^) | | | Topical | (Tyzeka^®^) | | | | | | Tenofovir DF + | | | Trifluridine | **Immune System | Lamivudine | | | (Viroptic^®^) - | Modulators (HBV | (Cimduo^®^) | | | Ophthal | / HCV)** | | | | | | Zidovudine | | | Idoxuridine | **Viral | (Retrovir^®^) | | | (Herplex^®^) - | Synthesis | | | | Ophthal | Inhibitors | Didanosine | | | | (HCV)** | (Videx^®^ and | | | Vidarabine | | Videx EC^®^) | | | (Vira-A^®^) - | **NS3/4A | | | | Ophthal | Protease | Stavudine | | | | Inhibitors | (Zerit^®^) | | | **[CYTOMEGALOVI | (HCV)** | | | | RUS | | Zidovudine + | | | AGENTS]{.underl | **Polymerase | Lamivudine | | | ine}** | Inhibitors | (Combivir^®^) | | | | (HCV)** | | | | **Nucleoside / | | Abacavir + | | | Nucleotide | NS5B inhibitor | Lamivudine + | | | Analogues** | | Zidovudine | | | | Sofosbuvir | (Trizivir^®^) | | | Ganciclovir | (Sovaldi^®^); | | | | (Cytovene^®^) | Dasabuvir | **Integrase | | | | (Combo) | Strand | | | Valganciclovir | | Inhibitors | | | (Valcyte^®^) | NS5A inhibitors | (INSTIs)** | | | | | | | | Cidofovir | Daclatasvir | **Nonnucleoside | | | (Vistide^®^) | (Daklinza^®^) | RTIs (NNRTIS)** | | | | | | | | **Nonnucleoside | Daclatasvir, | **Protease | | | (tide) | Elbasvir; | Inhibitors | | | Analogues** | Lepidasvir; | (PIs)** | | | | Ombitsavir; | | | | **DNA Terminase | Pribrentasvir, | | | | Complex | Velpatasvir | | | | Inhibitor** | (Combo Agents) | | | | | | | | | **CMV pUL97 | **Combination | | | | Kinase | Agents (HCV)** | | | | Inhibitor** | | | | | | Lepidasvir+Sofo | | | | **[ANTI-RESPIRA | sbuvir | | | | TORY | (Harvoni^®^) | | | | SYNCYTIAL VIRUS | NS5A+NS5B | | | | AGENTS]{.underl | | | | | ine}** | | | | | | | | | | **Viral | | | | | Synthesis | | | | | Inhibitors** | | | | | | | | | | **Fusion | | | | | Inhibitors** | | | | +-----------------+-----------------+-----------------+-----------------+